2025-04-26 - Analysis Report
## Recursion Pharmaceuticals Inc. (RXRX) Stock Review

**0) Key Figures:**

* **RXRX Cumulative Return:** -47.59%
* **VOO (S&P 500) Cumulative Return:** 16.99%
* **RXRX vs. VOO Return Difference:** -64.6%
* **Relative Return Difference (percentile):** 8.4% (This means RXRX's underperformance relative to VOO is at the 8.4th percentile of its historical range)
* **Current Closing Price:** $5.73

**1) Company Overview and Performance Comparison:**

Recursion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company leveraging AI and machine learning to discover and develop novel treatments for various diseases.  As shown above, RXRX significantly underperformed the S&P 500 (VOO) over the period reviewed, with a cumulative return difference of -64.6%.  This places its relative underperformance at the 8.4th percentile of its historical range against VOO.  The Alpha and Beta analysis shows consistently negative Alpha values and high Beta values across the periods, highlighting significant underperformance relative to the market (high sensitivity to market fluctuations) and a lack of outperformance beyond market movements. Market capitalization has also reduced in the same period.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 5.0% | 73.6% | -12.0% | 4.0 |
| 2022-2024  | 0.0% | 73.6% | -22.0% | 2.7 |
| 2023-2025  | 4.0% | 73.6% | -12.0% | 2.3 |


**2) Recent Price Movement:**

* **Closing Price:** $5.73
* **5-day Moving Average:** $5.62
* **20-day Moving Average:** $5.18
* **60-day Moving Average:** $6.70

The stock price is currently below all three moving averages, suggesting a bearish trend. The recent price change shows a minor decrease (-$0.02).


**3) Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.39 (Medium Risk)
* **RSI:** 69.76 (Approaching overbought territory)
* **PPO:** 2.77 (Positive, suggesting upward momentum, but needs further context)
* **20-day Relative Divergence Change:** -2.9% (Short-term bearish signal)
* **Expected Return:** -397.0% (This is a very significant negative expected return.  The context of this number is crucial:  is it based on a specific model? Over what time horizon?)

The technical indicators present a mixed picture. While the PPO suggests some upward momentum, the RSI is nearing overbought territory and the negative relative divergence suggests a bearish trend. The extremely negative expected return warrants further investigation into its calculation methodology and assumptions.  The recent small price drop (-0.35) is not significant enough to suggest a major event driving the price.

**4) Recent Earnings Analysis:**

| Date       | EPS      | Revenue     |
|------------|----------|-------------|
| 2024-11-06 | -$0.34   | $0.03 B     |
| 2024-08-08 | -$0.40   | $0.01 B     |
| 2024-05-09 | -$0.39   | $0.01 B     |
| 2023-11-09 | -$0.43   | $0.01 B     |
| 2024-11-06 | -$0.43   | $0.01 B     |


The company consistently reports negative EPS, and revenue is relatively low and inconsistent.  The most recent quarter shows a slight improvement in revenue, but remains negative in terms of profit.


**5) Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue    | Profit Margin |
|-------------|------------|---------------|
| 2024-12-31 | $0.00B     | -183.62%      |
| 2024-09-30 | $0.03B     | 53.69%        |
| 2024-06-30 | $0.01B     | 36.14%        |
| 2024-03-31 | $0.01B     | 17.23%        |
| 2023-12-31 | $0.01B     | 6.99%         |

**Capital and Profitability:**

| Quarter     | Equity     | ROE           |
|-------------|------------|---------------|
| 2024-12-31 | $1.03B     | -17.29%       |
| 2024-09-30 | $0.52B     | -18.27%       |
| 2024-06-30 | $0.58B     | -16.69%       |
| 2024-03-31 | $0.40B     | -22.78%       |
| 2023-12-31 | $0.46B     | -20.07%       |


The financial statements reveal significant financial challenges.  Negative profit margins and ROE consistently show the company is not yet profitable and is experiencing losses. The large swing in profit margin from Q3 to Q4 2024 warrants further investigation.  The increase in equity in Q4 2024 needs further examination to determine the cause.


**6) Overall Analysis:**

Recursion Pharmaceuticals (RXRX) is currently facing significant challenges.  The stock has significantly underperformed the S&P 500, showing consistent negative alpha and high beta.  Financial statements indicate ongoing losses and negative profitability.  While some technical indicators suggest potential upward momentum, the overall picture points to a high-risk investment. The extremely negative projected return (-397%) requires urgent clarification on its calculation methodology and assumptions.  Before considering any investment, thorough due diligence is critical, including a careful review of the -397% expected return calculation, the reasons behind the Q4 2024 profit margin swing and equity increase, and an assessment of the company's long-term viability and strategic plans.  A long-term investment strategy would only be advisable after a comprehensive understanding of these factors and a thorough risk assessment.
